Interhealth Nutraceuticals Inc

Astex Pharmaceuticals, a member of the Otsuka Group, is dedicated to advancing oncology through innovative research and development. The company focuses on discovering and developing targeted therapeutics for cancer treatment, with a robust clinical pipeline that includes various inhibitors and antagonists aimed at specific oncogenic pathways. Committed to corporate social responsibility, Astex emphasizes sustainability and collaboration within the healthcare community. Their proprietary products and programs, such as Tolinapant and ASTX660, aim to address unmet medical needs in oncology and beyond. Generated from the website

USA Tnma, located in Dublin, CA, is dedicated to providing high-quality nutritional supplements aimed at enhancing overall well-being. With a commitment to safety, affordability, and innovative formulations, the company offers a diverse range of products designed to improve mind, body, and performance. Guided by leading nutrition experts and backed by scientific research, USA Tnma ensures that its supplements deliver effective results while also being environmentally responsible; the company has achieved CarbonNeutral Company certification. Customers have reported significant improvements in their lives through the use of their products, which come in various convenient and palatable forms. Generated from the website

Peak Bio, Inc., based in Pleasanton, CA, is a biopharmaceutical company focused on developing innovative therapies for inflammatory rare and specialty diseases, as well as cancer. With a management team boasting over 50 years of industry experience, the company is dedicated to addressing significant unmet medical needs through its research and development in antibody-drug conjugates and small molecule therapeutics. One of their notable investigational therapies is PHP-303, a small molecule inhibitor of Neutrophil Elastase aimed at treating a rare genetic condition known as Alpha-1 Antitrypsin Deficiency (AATD). Additionally, Peak Bio is exploring novel toxins and antibody-drug conjugates (ADCs) that combine the precision of monoclonal antibodies with the potent effects of targeted small molecule therapies for oncology applications. Generated from the website